May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
The Compatibility of Vitrase® Combined With Avastin®
Author Affiliations & Notes
  • B.A. Aird
    ISTA Pharmaceuticals®, Inc., Irvine, CA.
    Research,
  • T.R. McNamara
    ISTA Pharmaceuticals®, Inc., Irvine, CA.
    Medical Affairs,
  • J.A. Gow
    ISTA Pharmaceuticals®, Inc., Irvine, CA.
    Medical Affairs,
  • C.K. Song
    ISTA Pharmaceuticals®, Inc., Irvine, CA.
    Medical Affairs,
  • T.W. Joe
    ISTA Pharmaceuticals®, Inc., Irvine, CA.
    Research,
  • G.A. Baklayan
    ISTA Pharmaceuticals®, Inc., Irvine, CA.
    Research,
  • Footnotes
    Commercial Relationships  B.A. Aird, ISTA Pharmaceuticals®, Inc., E; T.R. McNamara, ISTA Pharmaceuticals®, Inc., E; J.A. Gow, ISTA Pharmaceuticals®, Inc., E; C.K. Song, ISTA Pharmaceuticals®, Inc., E; T.W. Joe, ISTA Pharmaceuticals®, Inc., E; G.A. Baklayan, ISTA Pharmaceuticals®, Inc., E.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 5260. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      B.A. Aird, T.R. McNamara, J.A. Gow, C.K. Song, T.W. Joe, G.A. Baklayan; The Compatibility of Vitrase® Combined With Avastin® . Invest. Ophthalmol. Vis. Sci. 2006;47(13):5260.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine the compatibility of Vitrase® (hyaluronidase for injection) lyophilized, ovine (6200 USP units/vial) and Avastin® (bevacizumab), when combined.

Methods: : Vitrase (6200 USP units/vial) was reconstituted with 0.54 mL of sterile, unpreserved normal saline (0.9% sodium chloride for injection) and combined with Avastin to obtain concentrations of approximately 34 USP units per 50 µL Avastin, 68 USP units per 50 µL Avastin and 136 USP units per 50 µL Avastin. Sample preparations were visually inspected for precipitation over a period of 4 days. Hyaluronidase activity in the presence and absence of Avastin was determined using a validated turbidometric method. The ability of Avastin to bind vascular endothelial growth factor (VEGF) in the presence and absence of Vitrase was determined using the VEGF ELISA kit (Assay Designs Inc.), supplied with VEGF standard and plates pre–coated with the immobilized human anti–VEGF antibody.

Results: : All sample preparations (34 USP units of Vitrase per 50 µL of Avastin, 68 USP units of Vitrase per 50 µL of Avastin and 136 USP units of Vitrase per 50 µL of Avastin) remained free of turbidity over the course of 4 days. Vitrase activity remained unchanged and the ability of Avastin to bind VEGF also remained unchanged for all three sample concentrations of Vitrase.

Conclusions: : Various concentrations of Vitrase were found to be compatible when combined with Avastin. There were no visible signs of precipitation over a period of 4 days. Hyaluronidase activity and the ability of Avastin to bind VEGF remained unchanged for all three sample concentrations of Vitrase. In the in vitro setting, the combination of Vitrase and Avastin was found to retain full biological activity and stability for both constituents.

Keywords: age-related macular degeneration • choroid: neovascularization • macula/fovea 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×